Adnkronos Spinal muscular atrophy (SMA) has undergone radical innovation over the past decade thanks to the introduction of therapies that have demonstrated extremely high efficacy. Maintaining continuity of care for SMA patients is crucial because the currently available therapies allow for disease management, stability, and, in some cases, improvement.
The new risdiplam tablet therapy further improves this aspect from a logistical standpoint, both for the patient and for the hospitals and pharmacies that dispense the drug,” said Lorenzo Maggi, director of Neurology 4 at the Fondazione IRCCS Istituto Neurologico Carlo Besta in Milan, at the event “Brunch & Science: Let's talk about spinal muscular atrophy – The evolution of SMA treatment: when innovation paves the way to independence,” promoted by Roche Italia in Milan.
https://www.youtube.com/watch?v=JDCa_v6BQxo